A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen  by Ma, Xiao-Jun et al.
A R T I C L E
A two-gene expression ratio predicts clinical outcome in breast
cancer patients treated with tamoxifen
Xiao-Jun Ma,1 Zuncai Wang,2 Paula D. Ryan,3 Steven J. Isakoff,4,5 Anne Barmettler,2 Andrew Fuller,2
Beth Muir,2 Gayatry Mohapatra,2 Ranelle Salunga,1 J. Todd Tuggle,1 Yen Tran,1 Diem Tran,1
Ana Tassin,1 Paul Amon,1 Wilson Wang,1 Wei Wang,1 Edward Enright,1 Kimberly Stecker,1
Eden Estepa-Sabal,1 Barbara Smith,3 Jerry Younger,3 Ulysses Balis,2 James Michaelson,2
Atul Bhan,2 Karleen Habin,3 Thomas M. Baer,1 Joan Brugge,4 Daniel A. Haber,3
Mark G. Erlander,1 and Dennis C. Sgroi2
1Arcturus Bioscience, Inc., 2715 Loker Avenue West, Carlsbad, California 92008
2 Department of Pathology, Harvard Medical School, Molecular Pathology Research Unit, Massachusetts General Hospital,
Boston, Massachusetts 02129
3 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02129
4 Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
5 Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115
*Correspondence: dsgroi@partners.org (D.C.S.), merlander@arctur.com (M.G.E.)
Summary
Tamoxifen significantly reduces tumor recurrence in certain patients with early-stage estrogen receptor-positive breast
cancer, but markers predictive of treatment failure have not been identified. Here, we generated gene expression profiles
of hormone receptor-positive primary breast cancers in a set of 60 patients treated with adjuvant tamoxifen monotherapy.
An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which
outperformed existing biomarkers. Ectopic expression of HOXB13 in MCF10A breast epithelial cells enhances motility and
invasion in vitro, and its expression is increased in both preinvasive and invasive primary breast cancer. The HOXB13:IL17BR
expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast
cancer.
Introduction EBCTCG, 2001). However, 25% of ER/PR tumors, 66% of
ER/PR cases, and 55% of ER/PR cases fail to respond,
or develop early resistance to tamoxifen, through mechanismsTamoxifen is the antiestrogen agent most frequently prescribed
in women with both early-stage and metastatic hormone recep- that remain largely unclear (Clarke et al., 2003; Nicholson et al.,
2003; Osborne and Schiff, 2003). Currently, no reliable meanstor-positive breast cancer (reviewed in Clarke et al., 2003; Jor-
dan, 2002). In the adjuvant setting, tamoxifen therapy results in exist that allow the identification of patients who are at risk of
tumor recurrence in the setting of adjuvant tamoxifen monother-a 40%–50% reduction in the annual risk of recurrence, leading to
a 5.6% improvement in 10-year survival in lymph node-negative apy. In such patients, the use of alternative hormonal therapies,
such as the aromatase inhibitors letrozole and anastrozole (Buzdar,patients, and a corresponding 10.9% improvement in node-
positive patients (EBCTCG, 2001). Tamoxifen is thought to act 1998; Ellis et al., 2001; Goss et al., 2003), chemotherapeutic agents
(Colleoni et al., 2003a), or inhibitors of other signaling pathways,primarily as a competitive inhibitor of estrogen binding to estro-
gen receptor (ER), and it has no effect on tumor cells lacking such as trastuzmab and gefitinib (Atalay et al., 2003; Lichtner,
2003; Morris, 2002; Nicholson et al., 2003; Osborne and Schiff,ER expression. The absolute levels of ER expression, as well
as those of the progesterone receptor (PR, an indicator of a 2003), might improve clinical outcome. Therefore, the ability to
accurately predict tamoxifen treatment outcome should signifi-functional ER pathway), are currently the best predictors of
tamoxifen response in the clinical setting (Bardou et al., 2003; cantly advance the management of early-stage breast cancer.
S I G N I F I C A N C E
The majority of breast cancers express estrogen receptor (ER), and most patients with ER-positive tumors are treated with adjuvant
tamoxifen therapy. Approximately 40% of ER breast cancers fail to respond or eventually develop resistance to tamoxifen, leading
to disease progression. Current clinicopathological features including tumor stage and grade, and ERBB2 and EGFR expression fail
to accurately identify individuals who are at risk for tumor recurrence. Our results demonstrate that a simple two-gene expression
ratio of HOXB13 to IL17BR accurately predicts tumor recurrence in the setting of adjuvant tamoxifen monotherapy. Furthermore, the
association of HOXB13 overexpression with poor clinical outcome and with enhanced cell invasiveness in vitro raises the possibility
that it may play a role in breast cancer progression.
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Table 1. Patient and tumor characteristics in this study
Cohort 1 (frozen) Cohort 2 (FFPE)
Recurrence Nonrecurrence Recurrence Nonrecurrence
Size (cm) Total 28 32 10 10
Mean 2.7 2.1 1.9 1.7
Range 0.9–4.7 0.8–5.5 1.1–4.0 0.8–4.0
Grade 1 2 1 1 1
2 15 24 6 8
3 11 7 3 1
Nodes* 0 13 15 8 10
1–3 6 11 1 0
3 6 2 0 0
Age Mean 65.1 69.1 65.5 65.2
Range 48–84 54–85 54–93 57–74
DFS (Months) Mean 54.8 115.6 51.4 95.8
Range 5–137 61–169 15–117 25–123
Receptor status ER 27/28 32/32 10/10 10/10
PR 23/28 27/32 8/9* 10/10
*Cases with missing data omitted. DFS, disease-free survival; FFPE, formalin-fixed and paraffin-embedded.
Here, we performed a genome-wide microarray analysis archived primary biopsies. The resulting expression dataset was
first filtered based on overall variance of each gene, with the topof hormone receptor-positive invasive breast tumors from 60
patients treated with adjuvant tamoxifen alone, leading to the 5,475 high-variance genes (75th percentile) selected for further
analysis. Using this reduced dataset, a t test was performed onidentification of a two-gene expression ratio that is highly pre-
dictive of clinical outcome. This expression ratio can be readily each gene comparing tamoxifen nonrecurrences and recur-
rences, leading to the identification of 19 differentially expressedadapted to PCR-based analysis of standard formalin-fixed par-
affin-embedded (FFPE) clinical specimens, which we demon- genes at the p value cutoff of 0.001 (Figure 1A; Supplemental
Table S2). The probability of selecting this many or more differ-strated in an independent set of 20 patients with FFPE tissues.
Further, we demonstrate that the homeobox gene HOXB13 entially expressed genes by chance was estimated to be 0.04 by
randomly permuting the patient class with respect to treatment(Zeltser et al., 1996), whose overexpression is associated with
a poor outcome, confers invasive properties following ectopic outcome and repeating the t test procedure 2,000 times. This
analysis thus demonstrated the existence of statistically signifi-expression in a nontransformed mammary epithelial cell line.
Our results provide a simple molecular marker of clinical out- cant differences in gene expression between the primary breast
cancers of tamoxifen nonrecurrences and recurrences.come in ER-positive early-stage breast cancer and may provide
insight into molecular mechanisms underlying tamoxifen resis- To refine our analysis to the tumor cells and circumvent
potential variability due to stromal cell contamination, we reana-tance.
lyzed the same cohort following laser-capture microdissection
(LCM) of tumor cells within each tissue section (Bonner et al.,Results
1997; Emmert-Buck et al., 1996; Ma et al., 2003). Using vari-
ance-based gene filtering and t test screening identical to thatIdentification of differentially expressed genes
To identify gene expression patterns in hormone receptor-posi- utilized for the whole tissue section dataset, we identified 9
differentially expressed genes with p  0.001 (Figure 1B; Sup-tive, early-stage invasive breast cancers that might predict re-
sponse to hormonal therapy, we performed microarray gene plemental Table S3). Three genes were identified as differentially
expressed in both the LCM and whole tissue section analyses:expression analysis of tumors from 60 women uniformly treated
with adjuvant tamoxifen alone. These patients were identified the homeobox gene HOXB13 (identified twice as AI700363 and
BC007092), the interleukin 17B receptor IL17BR (AF208111),from a total of 103 ER-positive early-stage cases presenting to
Massachusetts General Hospital between 1987 and 1997, from and EST AI240933 (Figure 1). HOXB13 was overexpressed in
tamoxifen recurrence cases, whereas IL17BR and AI240933whom tumor specimens were snap-frozen and for whom mini-
mal 5-year follow-up was available (see Table 1 and Supple- were overexpressed in tamoxifen nonrecurrence cases.
Based on their identification as tumor-derived markers sig-mental Table S1 at http://www.cancercell.org/cgi/content/full/
5/6/607/DC1 for details). Within this cohort, 28 (46%) women nificantly associated with clinical outcome in two independent
analyses, we evaluated the prognostic utility of each of thesedeveloped distant metastasis with a median time to recurrence
of 4 years (“tamoxifen recurrences”) and 32 (54%) women re- three genes by itself and in combination with the others. To
define the sensitivity and specificity of HOXB13, IL17BR, andmained disease-free with median follow-up of 10 years (“tamoxi-
fen nonrecurrences”). Recurrence cases were matched with AI240933 expression as biomarkers of clinical outcome, we
used Receiver Operating Characteristic (ROC) analysis (Pepe,nonrecurrence cases with respect to TNM staging (Singletary
et al., 2002) and tumor grade (Dalton et al., 2000). 2000). For data derived from whole tissue sections, the Area
Under the Curve (AUC) values for IL17BR, HOXB13, andGene expression profiling was performed using a 22,000-
gene oligonucleotide microarray. In the initial analysis, we iso- AI240933 were 0.79, 0.67, and 0.81, respectively (Table 2; Sup-
plemental Figure S1). ROC analysis of the data generated fromlated RNA from frozen tumor-tissue sections taken from the
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Figure 1. Heatmap of differential gene expres-
sion between tamoxifen responders and nonre-
sponders
A: 19 genes identified in the tissue sections da-
taset.
B: 9 genes identified in the LCM dataset. Genes
identified in bold are present in both lists. The row
of yellow and blue bars below each dendro-
gram indicates recurrences and nonrecur-
rences, respectively. Bottom, color scale bar.
p values are from a two-sample t test and unad-
justed for multiple testing. See Supplemental Ta-
bles S1 and S2 for details.
the microdissected tumor cells yielded AUC values of 0.76, 0.8, correlated with tamoxifen response (Bardou et al., 2003; Fernan-
and 0.76 for these genes (Table 2; Supplemental Figure S1). A dez et al., 1983; Ferno et al., 2000; Nardelli et al., 1986; Osborne
statistical test of significance indicated that these AUC values et al., 1980). Therefore, mRNA measurements for ER and PR
are all significantly greater than 0.5, the expected value from based on the microarray datasets were used to assess their
the null model that predicts clinical outcome randomly (Table 2). predictive capacity for tamoxifen treatment outcome. In addi-
Therefore, these three genes have potential utility for predicting tion, growth factor signaling pathways (EGFR, ERBB2) are
clinical outcome of patients treated with adjuvant tamoxifen. thought to negatively regulate estrogen-dependent signaling,
As comparison, we analyzed markers that are currently use- and hence contribute to loss of responsiveness to tamoxifen
ful in evaluating the likelihood of response to tamoxifen. All (Dowsett, 2001; Lichtner, 2003; Nicholson et al., 2003; Osborne
but one of the 60 cases were ER according to clinical tests and Schiff, 2003). ROC analysis of the gene expression levels
performed at diagnosis (Supplemental Table S1), but this binary of these genes confirmed their correlation with clinical outcome,
receptor status is not informative for potential differences in but with AUC values ranging only from 0.55 to 0.69, reaching
response to tamoxifen when essentially all patients are ER. statistical significance for PGR and ERBB2 (Table 2). The LCM
The quantitative levels of ER (gene symbol ESR1) and progester- dataset is particularly relevant, since EGFR, ERBB2, ESR1, and
one receptor (PR, gene symbol PGR) are known to be positively PGR are currently measured at the tumor cell level using either
immunohistochemistry or fluorescence in situ hybridization. As
individual markers of clinical outcome, HOXB13, IL17BR, and
AI240933 outperformed ESR1, PGR, EGFR, and ERBB2 (Table 2).
Table 2. ROC analysis of using IL17BR, AI240933, and HOXB13 expression
to predict tamoxifen treatment outcome
HOXB13:IL17BR expression ratio is a robust composite
Tissue sections LCM predictor of outcome
Since HOXB13 and IL17BR have opposing patterns of expres-AUC p value AUC p value
sion (Figure 1), we examined whether the expression ratio of
IL17BR 0.79 1.58E-06 0.76 2.73E-05
HOXB13 over IL17BR provides a better composite predictorAI240933 0.81 3.02E-08 0.76 1.59E-05
of tamoxifen response. Indeed, both t test and ROC analysesHOXB13 0.67 0.012 0.79 9.94E-07
ESR1 0.55 0.277 0.63 0.038 demonstrated that the two-gene ratio had a stronger correlation
PGR 0.63 0.036 0.63 0.033 with treatment outcome than either gene alone, both in the
ERBB2 0.69 0.004 0.64 0.027
whole tissue sections and LCM datasets (Table 3). AUC valuesEGFR 0.56 0.200 0.61 0.068
for HOXB13:IL17BR reached 0.81 for the tissue sections dataset
AUC, area under the curve; p values are AUC  0.5. and 0.84 for the LCM dataset. Pairing HOXB13 with AI240933 or
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Table 3. HOXB13:IL17BR ratio is a stronger predictor of treatment outcome
t test ROC
t statistic p value AUC p value
Tissue section IL17BR 4.15 1.15E-04 0.79 1.58E-06
HOXB13 3.57 1.03E-03 0.67 0.01
HOXB13:IL17BR 4.91 1.48E-05 0.81 1.08E-07
LCM IL17BR 3.70 5.44E-04 0.76 2.73E-05
HOXB13 4.39 8.00E-05 0.79 9.94E-07
HOXB13:IL17BR 5.42 2.47E-06 0.84 4.40E-11
AUC, area under the curve; p values are AUC  0.5.
analysis of all three markers together did not provide additional that the expression ratio of HOXB13:IL17BR is a strong indepen-
power (data not shown). dent predictor of treatment outcome in the setting of adjuvant
We compared the HOXB13:IL17BR ratio to well-established tamoxifen therapy.
prognostic factors for breast cancer, such as patient age, tumor
size, grade, and lymph node status (Fitzgibbons et al., 2000). Independent validation of HOXB13:IL17BR expression
Univariate logistic regression analysis indicated that only tumor ratio to predict tamoxifen treatment outcome
size was marginally significant in this cohort (p 0.04); this was The reduction of a complex microarray signature to a two-gene
not surprising given that the nonrecurrence group was closely expression ratio allows the use of simpler detection strategies,
matched to the recurrence group with respect to tumor size, such as real-time quantitative PCR (RT-QPCR) analysis. We
tumor grade, and lymph node status during patient selection. therefore analyzed the HOXB13:IL17BR expression ratio by RT-
Among the known positive (ESR1 and PGR) and negative QPCR using tissue sections that were available from 59 of the
(ERBB2 and EGFR) predictors of tamoxifen response, ROC 60 frozen specimens (Figure 2A). RT-QPCR data were highly
analysis of the tissue sections data indicated that only PGR concordant with the microarray data of frozen tumor specimens
and ERBB2 were significant (Table 2). Therefore, we compared (Pearson correlation coefficient r  0.83 for HOXB13, 0.93 for
logistic regression models containing the HOXB13:IL17BR ratio IL17BR). In addition, the PCR-derived HOXB13:IL17BR ratios,
either by itself or in combination with tumor size, and expression represented as CTs, where CT is the PCR amplification cycles
levels of PGR and ERBB2 (Table 4). The HOXB13:IL17BR ratio to reach a predetermined threshold amount (e.g., Figures 2A
alone was a highly significant predictor (p  0.0003) and had and 2B) and CT is the CT difference between HOXB13 and
an odds ratio of 10.2 (95% CI 2.9–35.6). In the multivariate IL17BR, were highly correlated with the microarray-derived data
model, HOXB13:IL17BR ratio is the only significant variable (p (r 0.83) and with treatment outcome (t test p 5.8e-06, Figure
0.002) with an odds ratio of 7.3 (95% CI 2.1–26). Controlling 2C). Thus, conventional RT-QPCR analysis for the expression
for tumor size, tumor grade, and nodal status in patient selection ratio of HOXB13 to IL17BR appears to be equivalent to micro-
is an effective strategy to reveal potential gene expression pat- array-based analysis of frozen tumor specimens.
terns predicting clinical outcome independent of known prog- One significant benefit of using a simple two-gene ratio test
nostic factors (Gruvberger et al., 2003). However, the relative is the possibility of applying the test in routine clinical speci-
predictive power of HOXB13:IL17BR in the context of these mens, which are mostly formalin-fixed and paraffin-embedded
known prognostic factors will need to be assessed in larger (FFPE). To demonstrate the predictive utility of the HOX-
population-based patient cohorts. The inclusion of only 10 PR- B13:IL17BR expression ratio in an independent patient cohort of
negative patients may also underestimate the predictive utility FFPE specimens, we identified 20 additional ER-positive early-
of PR in this cohort. Nonetheless, these results demonstrated stage primary breast tumors from women treated with adjuvant
tamoxifen monotherapy between 1991 and 2000, for whom both
medical records and FFPE blocks were available. Of the 20
archival cases, 10 had recurred with a median time to recurrence
Table 4. Logistic regression analysis
of 5 years, and 10 had remained disease-free with a median
Univariate model follow up of 9 years (see Table 1 and Supplemental Table S4 for
Predictor Odds ratio 95% CI p value details). RNA was extracted from FFPE tissue sections, linearly
amplified, and used as template for RT-QPCR analysis. Consis-HOXB13:IL17BR 10.17 2.9–35.6 0.0003
tent with the results of the frozen cohort, the HOXB13:IL17BR
Multivariate model
expression ratio in this independent patient cohort was highly
Predictors Odds ratio 95% CI p value correlated with clinical outcome (t test p  0.024) with higher
Tumor size 1.5 0.7–3.5 0.3289
HOXB13 expression (lower CTs) correlating with poor outcomePGR 0.8 0.3–1.8 0.5600
(Figure 2D).ERBB2 1.7 0.8–3.8 0.1620
HOXB13:IL17BR 7.3 2.1–26.3 0.0022 To test the predictive accuracy of the HOXB13:IL17BR ratio,
we used the RT-QPCR data from the frozen tissue sections (nAll predictors are continuous variables. Gene expression values were from
microarray measurements. Odds ratio is the interquartile odds ratio, based 59) to build a logistic regression model. The model fitted well
on the difference of a predictor from its lower quartile (0.25) to its upper to this training set, with an overall accuracy of 81%, and the
quartile (0.75); CI, confidence interval. positive and negative predictive values were 81% and 82%,
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the FFPE cohorts (Figures 2E and 2F). Therefore, the HOX-
B13:IL17BR ratio model defined in the frozen cohort had compa-
rable performance in an independent set of 20 FFPE cases,
suggesting the potential of this two-gene ratio as an accurate
predictive biomarker of clinical outcome for tamoxifen mono-
therapy.
HOXB13 stimulates mammary epithelial
cell migration and invasion
The reduction of our tamoxifen response signature to two genes
raised the possibility that these genes may not only be markers
of clinical outcome but may be involved in breast tumorigenesis.
Little information exists in the literature linking IL17BR to breast
cancer. In contrast, HOXB13 has been shown to be overex-
pressed in a small number of breast cancer tissue samples (n
11) (Cantile et al., 2003). Indeed, RT-QPCR analysis of LCM-
procured normal and malignant breast epithelial cells from our
expanded, previously published cohort (n 45) (Ma et al., 2003)
demonstrated that compared to normal breast epithelial cells,
the mean expression levels of HOXB13 were significantly higher
in both ductal carcinoma in situ (DCIS, p  0.002) and invasive
ductal carcinoma (IDC, p  0.006) (Figure 3A). Compared to
patient-matched normals, 56% DCIS or IDC cases overex-
pressed HOXB13 by 2-fold. Furthermore, RNA in situ hybrid-
ization confirmed the tumor cell-specific expression of HOXB13
(Figure 3B). Interestingly, a subset of normal breast specimens
demonstrated expression of HOXB13 in terminal duct lobular
unit, raising the possibility that it may play a role in normal
mammary physiology (Figure 3B).
To investigate the potential biological function of HOXB13,
we expressed a retroviral construct in MCF-10A cells, a non-
transformed human mammary epithelial cell line spontaneously
Figure 2. Prediction of clinical outcome by HOXB13:IL17BR ratio derived from normal breast tissue (Soule et al., 1990). Ectopic
A and B: HOXB13 (A) and IL17BR (B) real-time quantitative PCR for recurrence expression of HOXB13 in MCF10A was confirmed by RT-QPCR
case 1085 and nonrecurrence case 607. (Figure 3C, insert). Cells expressing HOXB13 displayed distinct
C and D: Dot plot of HOXB13:IL17BR ratios according to clinical outcome morphological changes, characterized by a reduction in epithe-
(0  nonrecurrence, 1  recurrence) in the 59 frozen sections (C) and 20
lial-type junctions (data not shown). Compared to cells infectedFFPE sections (D). In each plot, the dashed line denotes the cutoff point
with the empty vector, MCF10A cells expressing HOXB13 haddetermined by logistic regression analysis; numerals represent the number
of nonrecurrences and recurrences. a 5-fold increase in cell motility in trans-well migration assays
E and F: Kaplan-Meier disease-free survival curves for the frozen (E) and in the presence of EGF (Figure 3C). Invasion through a Matrigel-
FFPE (F) cohorts comparing patients with HOXB13:IL17BR ratios above (high
coated modified Boyden chamber, a well-established assayH:I) or below (low H:I) the cutoff point defined in the logistic regression
correlated with metastatic potential in vivo (Albini et al., 1987;model.
Repesh, 1989), was also enhanced 5-fold by HOXB13 expres-
sion in the presence of EGF (Figure 3D). These observations
suggest that HOXB13 may regulate a pathway that functions
synergistically with EGF-dependent signaling to stimulate cellrespectively (the cutoff point derived from the model was indi-
motility and invasion in vitro.cated by the dashed line in Figure 2C). Because we identified
the two genes and built the model in the same patient cohort,
Discussionthese performance estimates may be biased. Therefore, we
applied the model directly to the 20 independent patients in the
Previous studies linking gene expression profiles to clinical out-FFPE cohort. In the resulting “honest” prediction, treatment
come in breast cancer have demonstrated that the potentialoutcome for 16 of the 20 patients was correctly predicted with
an overall accuracy of 80% and positive and negative predictive for distant metastasis and overall survival probability may be
attributable to biological characteristics of the primary tumor atvalues of 87% and 75%, respectively (Figure 2D). The probability
of correctly predicting 16 of 20 cases by chance was 0.01 (exact the time of diagnosis (Huang et al., 2003; Sorlie et al., 2001,
2003; Sotiriou et al., 2003; van de Vijver et al., 2002; van ’t Veerbinomial test; 95% confidence interval 56%–94%), demonstra-
ting the statistical significance of the two-gene ratio test in the et al., 2002). In particular, a 70-gene expression signature has
proven to be a strong prognostic factor, outperforming all knownindependent FFPE cohort. To further illustrate the predictive
ability of HOXB13:IL17BR ratio, the two patient groups stratified clinicopathological parameters. However, in those studies, pa-
tients either received no adjuvant therapy (van ’t Veer et al.,by the HOXB13:IL17BR ratio cutoff point exhibited significantly
different disease-free survival curves in both the frozen and 2002) or were treated nonuniformly with hormonal and chemo-
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Figure 3. HOXB13 expression in breast cancer and its ectopic expression enhances cell motility and invasion
A: Relative quantitative HOXB13 gene expression values in normal (N, n  45), DCIS (n  42), and IDC (n  29) cases. Error bars denote 95% confidence
intervals.
B: In situ hybridization of HOXB13 mRNA. DIG11UTP-labeled RNA probes with anti-sense hybridization to human breast epithelium of (i) the normal terminal
duct lobular unit (200 magnification), (ii) ductal carcinoma in situ (400 magnification), and (iii) invasive ductal carcinoma (400 magnification), and
sense probe hybridization to (iv) invasive ductal carcinoma (400 magnification). Inserts represent select regions of each field at 1000 magnification. L,
S, and T denote lobule, stroma, and tumor, respectively.
C: Migration assay. The mean numbers of cells that migrated through the transwell filter per 20 field are shown  standard deviation of triplicate wells;
insert represents ectopic expression of HOXB13 in MCF10A cells; reverse transcription PCR analysis of HOXB13 from expression constructs with pBABE vector
alone (lane 1) or HOXB13 (lane 2).
D: Invasion assay. The mean number of cells that invaded is shown. Error bars indicate one standard deviation. *, p  0.05 compared to control cells
(MCF10A cells infected with pBABE).
therapeutic regimens (Huang et al., 2003; Sorlie et al., 2001, ratio test in a microarray data set containing 45 patients with
ER breast cancer treated with tamoxifen monotherapy (Soti-2003; Sotiriou et al., 2003; van de Vijver et al., 2002). Patients
with ER-positive early-stage breast cancer treated with tamoxi- riou et al., 2003). However, the published cDNA microarray
dataset did not include HOXB13 or IL17BR. Even when all 25fen alone, such as the cohorts studied here, represent only a
subset of the population tested with the 70-gene signature. Of genes identified in this study (Figures 1A and 1B) were consid-
ered, only two genes (IL1R2 and APS) were present on theirnote, 61 of the genes in the 70-gene signature were present on
the microarray used in our study, but no significant association cDNA microarray, making it impossible to evaluate our pre-
dictive signature.with clinical outcome was observed in our patient cohorts (data
not shown). Conversely, the HOXB13:IL17BR ratio identified in The observation that a simple expression ratio of two genes,
HOXB13:IL17BR, accurately predicts tumor recurrence in adju-our tamoxifen-treated cohorts is not effective in predicting clini-
cal outcome of patients receiving no adjuvant therapy in the vant tamoxifen-treated patients with early-stage ER-positive
breast cancer is limited by the size of patient cohorts in thisvan ’t Veer study (data not shown). Hence, the genes identified
here as correlated with clinical outcome in the setting of adjuvant study and will require confirmation in a larger population-based
cohort. Furthermore, it remains to be determined whether thistamoxifen monotherapy may differ from those associated with
inherent biological properties of a more diverse collection of two-gene ratio predicts a tumor’s response to tamoxifen or
its intrinsic aggressiveness, or both. A similarly case-matchedbreast cancers. We also attempted to evaluate our two-gene
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Experimental procedurescohort of untreated patients will be required to address this
issue. If confirmed, this simple assay may prove helpful in identi-
Patient and tumor selectionfying patients who may benefit from more complete ablation of
Patient inclusion criteria for this study were: women diagnosed at the Massa-
estrogen signaling using aromatase inhibitors (Goss et al., 2003) chusetts General Hospital (MGH) between 1987 and 2000 with hormone
or from the addition of chemotherapeutic agents (Colleoni et receptor-positive breast cancer, treatment with standard breast surgery
al., 2003b). Whereas most reported prognostic signatures in (modified radical mastectomy or lumpectomy), and radiation followed by
five years of systemic adjuvant tamoxifen; no patient received chemotherapyhuman cancer have involved a large number of markers and
prior to recurrence. Clinical and follow-up data were derived from the MGHrequired microarray-based analysis, we were able to reduce the
tumor registry. There were no missing registry data and all available medicaltamoxifen outcome signature to a two-gene ratio with no loss
records were reviewed as a second tier of data confirmation. This studyof accuracy. The application of a simple two-gene PCR-based
was approved by the institutional review board of the MGH in accordance
assay to standard FFPE clinical tissues will allow for broader with federal human research study guidelines.
access and utilization of this technology in the clinical setting. All tumor specimens collected at the time of initial diagnosis were ob-
Little is known about the relevance of HOXB13 in breast tained from frozen and formalin-fixed paraffin-embedded (FFPE) tissue re-
positories at the Massachusetts General Hospital. Tumor samples withcancer biology. Homeobox genes encode transcriptional regu-
greater than 20% tumor cells were selected with a median of greater thanlators implicated in normal organ development, whose disrup-
75% for all samples. Each sample was evaluated for the following features:tion has been most clearly linked with hematopoietic malignan-
tumor type (ductal versus lobular), tumor size, and Nottingham combined
cies (reviewed in Abate-Shen, 2002; Maulbecker and Gruss, histological grade (Dalton et al., 2000). Estrogen and progesterone receptor
1993). However, expression of HOXC8 was recently shown to expression were determined by biochemical hormone binding analysis and/
be upregulated in prostate cancer and to suppress androgen or by immunohistochemical staining as described (Harvey et al., 1999). More
receptor signaling (Miller et al., 2003), raising the possibility that specifically, ER positivity was defined as greater than 10 fmol/mg tumor
tissue and greater than 1% nuclear staining or immunohistochemistry (IHC)some homeobox genes may interact with hormone receptor
score of at least 3 for the biochemical and immunohistochemical assayssignaling. Consistent with a previous report (Cantile et al., 2003),
(Harvey et al., 1999), respectively; all but three tumors (2 recurrences andwe demonstrated that HOXB13 was frequently upregulated in
1 nonrecurrence) demonstrated greater than 10% ER staining by IHC (see
breast cancer cells relative to normal breast epithelial cells. Of Supplemental Table S1). Immunohistochemistry for Her-2/neu protein ex-
note, we detected HOXB13 expression in normal cells of the pression was performed on paraffin-embedded or frozen tissue sections
terminal duct lobular unit, the anatomic substructure of the hu- using anti-HER-2/neu polyclonal antibody (Dako Corp, Carpinteria CA, dilu-
tion 1:300) or anti-HER2/neu monoclonal antibody NCL-CB11 (Novocastraman breast from which breast cancer arises, suggesting that
Laboratories, Newcastle upon Tyne, UK, dilution 1:50) and employing stan-this homeobox protein may play a role in breast development
dard immunoperoxidase techniques (Jacobs et al., 1999). The membraneand physiology. Importantly, ectopic expression of HOXB13
staining of cells was scored as no or weak staining (0–1 or negative),in MCF10A cells potentiates EGF-induced cell migration and
moderate staining (2 or indeterminate) and strong staining (3 or positive);
invasion, suggesting that HOXB13 may directly contribute to in our experience, most tumors showing 2 staining do not demonstrate
tumor invasion and metastasis. Functional cooperation between HER-2/neu amplification by FISH. Tumors from recurrence cases were
HOXB13 and EGFR signaling pathways may be relevant in the matched to the nonrecurrences with respect to TNM staging and tumor
grade (Dalton et al., 2000; Singletary et al., 2002).context of tamoxifen resistance, since activation of growth fac-
tor signaling pathways can cause tamoxifen-resistant tumor
LCM and RNA isolation and amplificationgrowth (Clarke et al., 2003; Nicholson et al., 1994; Osborne and
With each frozen tumor sample within the 60-case cohort, RNA was isolatedSchiff, 2003). Given the known role of ERBB2 overexpression in
from both a whole tissue section of 8 	m in thickness and a highly enriched
human breast cancer, the apparent in vitro interaction between population of 4,000–5,000 malignant epithelial cells procured by laser cap-
HOXB13 expression and EGF signaling pathways may also point ture microdissection using a PixCell IIe LCM system (Arcturus, Mountain
to possible therapeutic options in tumors with high expression of View, CA). From each tumor sample within the 20-case test set, RNA was
isolated from four 8 	m-thick FFPE tissue sections using the Paradise Re-HOXB13. In fact, targeting the ERBB2 pathway through blocking
agent System (Arcturus, Mountain View, CA). Isolated RNA was subjectedantibodies (Herceptin) has been suggested in the context of
to DNase treatment followed by one round of T7 polymerase in vitro tran-tamoxifen resistance based on the link between activation of
scription using the RiboAmp kit (frozen samples) or the Paradise systemgrowth factor signaling pathways and estrogen-independent
(FFPE samples) according to manufacturer’s instructions (Arcturus, Moun-
tumor growth (Clarke et al., 2003; Nicholson et al., 2003; Os- tain View, CA). Labeled cRNA was generated by a second round of T7-
borne and Schiff, 2003). HOXB13 may also have a direct effect based RNA in vitro transcription in the presence of 5-[3-Aminoallyl]uridine
on ER signaling, since homeobox proteins have been shown to 5
-triphosphate (Sigma-Aldrich, St. Louis, MO). Universal Human Reference
RNA (Stratagene, San Diego, CA) was amplified in the same manner. Theinhibit the histone acetyltransferase activity of CBP/p300 (Shen
purified aRNA was later conjugated to Cy5 (experimental samples) or Cy3et al., 2001), a key coactivator for ER-dependent transcriptional
(reference sample) dye (Amersham Biosciences).regulation (Chakravarti et al., 1996; Hanstein et al., 1996). There-
fore, HOXB13 may be involved directly and indirectly in the
Data analysis
modulation of ER signaling pathways, a possibility that is of Raw data are available in GEO (http://www.ncbi.nlm.nih.gov/geo/, accession
particular interest given its clinical correlation with tamoxifen numbers GSE1378 and GSE1379). A custom-designed 22,000-gene oligo-
resistance. nucleotide (60mer) microarray was fabricated using ink-jet in-situ synthesis
technology (Agilent Technologies, Palo Alto, CA). Cy5-labeled sample RNAIn summary, our findings demonstrate the utility of a two-
and Cy3-labeled reference RNA were cohybridized at 65C, 1 hybridizationgene expression biomarker in identifying a subset of patients
buffer (Agilent Technologies). Slides were washed at 37C with 0.1 SSC/with ER-positive breast cancer who are at risk for tumor recur-
0.005% Triton X-102. Image analysis was performed using Agilent’s imagerence in the setting of tamoxifen therapy, who may benefit from
analysis software.
alternative therapeutic options. Furthermore, our results have Raw Cy5/Cy3 ratios per array were normalized using nonlinear local
the potential to open new avenues of research into the molecular regression (loess, Yang et al., 2002); no background adjustment was made
due to generally low local background values. Between-array normalizationmechanisms of resistance to tamoxifen.
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was achieved by subtracting the median log2 ratios gene-wise across all packaging cells as described (Ory et al., 1996), and stable pools of MCF-
10A cells were generated by retroviral infection as described (Debnath etarrays. The variance of each gene over all samples was calculated and the
top 25% high variance genes (5,475) selected for further analysis. Identifica- al., 2003) using 2 	g/ml puromycin for selection. Control cells were MCF10
cells infected with the empty pBABE vector.tion and permutation testing for significance of differential gene expression
were performed using BRB ArrayTools, developed by Richard Simon and
Amy Peng (http://linus.nci.nih.gov/BRB-ArrayTools.html). Hierarchical clus- Trans-well migration and invasion assay
In vitro migration and invasion assays were performed using 24-well modifiedter analysis was performed with GeneMaths software (Applied-Maths, Bel-
gium) using cosine correlation as distance and complete linkage clustering. Boyden chamber trans-well with PET (polyethylene terephthalate) mem-
branes containing 8 micron pores (BD BioCoat). Uncoated membranes wereAll other statistical procedures (two-sample t test, receiver operating charac-
teristic analysis, logistic regression, and survival analysis) were performed used for migration assays, and Matrigel-coated membranes were used for
invasion (Repesh, 1989). Stable pools of MCF-10A cells infected with retrovi-in the open-source R statistical environment (http://www.r-project.org). Sta-
ral constructs were maintained in growth medium until the day of the assay.tistical test of significance of ROC curves was by the method of DeLong et
5  104 cells in 100 	l of assay medium were seeded in the upper chamber,al. (1988) as implemented by Doug Mahoney and Beth Atkinson in their
and 500 	l assay medium with or without 20 ng/ml EGF was added to theS-Plus roc package (http://www.mayo.edu/hsr/Sfunc.html). Disease-free
lower chamber. Cells were incubated at 37C for 24 hr, then fixed in 70%survival was calculated from the date of diagnosis. Events were scored as
ethanol for 20 min, rinsed with PBS, and stained with DAPI (500 ng/ml).the first distant metastasis, and patients remaining disease-free at the last
Cells that remained on the upper surface were mechanically removed withfollow-up were censored. Survival curves were calculated by the Kaplan-
a cotton swab. Cells remaining on the underside were counted (5 fields atMeier estimates and compared by log-rank tests. To build a predictive model
20 magnification per trans-well). Trans-wells were plated in triplicates andusing HOXB13 and IL17BR, raw CT values from RT-QPCR were normalized
the results were averaged. Invasion through a Matrigel-coated modifiedacross the sample set (subtracting the mean CT and dividing by the standard
Boyden chamber was assayed as described (Albini et al., 1987; Repesh,deviation), and the two-gene ratio was the difference of normalized CT values
1989).(HOXB13  IL17BR); normalization was done separately for the frozen and
FFPE cohorts. The two-gene ratio was then used in a univariate logistic
Acknowledgmentsregression model, and the cutoff point for predicting recurrences  inter-
cept/ coefficient for the ratio, both of which were derived from the model.
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